Experts Analyze Benefits, Opportunities and Challenges of Medicare Part D
Special themed issue of research in social and administrative pharmacy
Philadelphia, PA, June 29, 2010 –The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Medicare Part D) added prescription drug coverage to Medicare beginning in January 2006. This has dramatically reshaped the prescription drug insurance market and has had significant effects on insurers, beneficiaries, and providers. For researchers, it has provided a rich source of research questions to examine. A special themed issue of Research in Social and Administrative Pharmacy analyzes the benefits, opportunities and challenges afforded by the Medicare Part D drug benefit program from different perspectives – from providers and pharmacists to patients.
Guest editors Julie M. Urmie, Ph.D., and William R. Doucette, Ph.D., both of the Department of Pharmacy Practice and Science, University of Iowa, Iowa City, have assembled a group of experts in their respective fields to provide critical insights into how Medicare Part D has impacted:
- Prescription costs
- Use of generic drugs
- Coverage for previously uninsured Medicare beneficiaries
- Chain and independent pharmacies and pharmacists
- Reimbursement from Part D plans
- Beneficiary experiences with Medicare Part D and access to MTM (Medication Therapy Management) services
“Medicare Part D has been a rich source of research opportunities since its implementation in 2006,” commented Professor Urmie and Professor Doucette. “Although researchers have made strides in understanding its impact on various constituencies, the complexity and continually evolving nature of Part D will yield many future research prospects. We hope that the articles in this theme issue of RSAP contribute a usable baseline for such future research and we look forward to seeing an abundance of future research in this area.”
Two articles discuss the cost of Part D. In the first, David A. Mott and coauthors studied whether Medicare Part D had the intended effects of helping individuals with high financial burden without increasing use among individuals with low financial burden. Part D resulted in significantly increased drug use for those with the highest pre-part D out-of-pocket drug spending relative to individuals with the lowest pre-Part D drug spending burden. Significant decreases in out-of-pocket drug spending for those individuals with the highest Part D out-of-pocket spending relative to individuals with moderate and the lowest pre-Part D drug spending burden were also noted.
Beneficiaries of Medicare Part D must decide whether to enroll in a stand-alone prescription drug plan (PDP) and receive other medical coverage through the Medicare Part A and B fee-for-service benefit or to enroll in a Medicare Advantage prescription drug plan (MA-PD) providing comprehensive care. Richard R. Cline and colleagues examined factors impacting this decision. For example, individuals living in rural areas, who reported non-white ethnicity, with annual household incomes between $25,000 and $50,000, and who reported knowing their current pharmacist "extremely well" were less likely to enroll in a Medicare Advantage prescription drug program. A wide variety of variables appear to be associated with Medicare Part D enrollment decisions.
Amber M. Goedken and coauthors administered online surveys to elderly Medicare beneficiaries before and after implementation of Medicare Part D to examine the cost-sharing they faced and the medications they used. They found that copayment differentials between generic and brand drugs in three-tier Part D plans were greater than in employer plans. The generic drug utilization rates of the uninsured and beneficiaries with Part D were lower than those of beneficiaries with employer coverage but similar to each other.
The next two articles examine the impact of Medicare Part D on independent and chain pharmacies. James D. Bono and Stephanie Yvonne-Crawford report on focus groups held with rural Illinois pharmacists shortly after the implementation of Medicare Part D. They explored the impact on the rural pharmacy environment, in particular looking for any similarities or differences in the perceptions of rural independent and chainstore pharmacists. The authors found that rural independent pharmacies may be more highly impacted, which in turn could jeopardize their viability in serving patients in these communities.
Su Zhang and co-authors surveyed independent pharmacies to assess their satisfaction with Medicare Part D contracts. If prevalent, low satisfaction could reduce the access of Medicare Part D beneficiaries to pharmacist services. Independent pharmacy owners’ satisfaction was most influenced by equity or fairness, contending, a willingness to negotiate, generic rate bonuses and medication therapy management (MTM) payments.
Medication therapy management (MTM) is a relatively new service for Medicare Part D beneficiaries, and MTM best practices are not established. Leticia R. Moczygemba and co-authors assessed patient satisfaction with a pharmacist-provided telephone Medicare Part D MTM program. Overall, patients were satisfied with the MTM program. They indicated that they liked receiving MTM via the telephone, but would also be willing to attend a face-to-face MTM consultation.
Pharmacists are also on a learning curve with MTM services. Beth A. Martin and her colleagues developed a scale to measure community pharmacists’ self-efficacy in performing medication therapy management services. The 3-factor 14-item scale can be used to measure change in self-efficacy as MTM programs expand, identify specific training interventions, and target pharmacists for inclusion in future initiatives.
# # #
The special issue of Research in Social and Administrative Pharmacy, Volume 6, Issue 2, (June 2010) is available now. The journal is published by Elsevier.
Full text of the articles is available to journalists upon request. To obtain copies contact Chris Baumle at 215-239-3731 or email@example.com. Journalists wishing to set up interviews with the guest editors or individual authors should contact William R. Doucette, Ph.D. at 319-335-8786; firstname.lastname@example.org, or Julie M. Urmie, Ph.D. at 319-335-8616;email@example.com.
Research In Social And Administrative Pharmacy
Volume 6, Issue 2 (June 2010)
William R. Doucette, Ph.D
Department of Pharmacy Practice and Science
University of Iowa, Iowa City
Julie M. Urmie, Ph.D.
Department of Pharmacy Practice and Science
University of Iowa, Iowa City
Table of Contents
Understanding the effects of Medicare Part D from key stakeholders’ perspectives: Important progress, but abundant research opportunities remain
Julie M. Urmie, Ph.D., William R. Doucette, Ph.D.
Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?
David A. Mott, Ph.D., Joshua M. Thorpe, Ph.D., Carolyn T. Thorpe, Ph.D., David H. Kreling, Ph.D., Abhijit S. Gadkari, Ph.D.
Impact of cost sharing on prescription drugs used by Medicare beneficiaries
Amber M. Goedken, Pharm.D., Julie M. Urmie, Ph.D., Karen B. Farris, Ph.D., William R. Doucette, Ph.D.
Impact of Medicare Part D on independent and chain community pharmacies in rural Illinois—A qualitative study 110
James D. Bono, M.H.A., Stephanie Yvonne-Crawford, Ph.D.
Factors associated with independent pharmacy owners’ satisfaction with Medicare Part D contracts
Su Zhang, Pharm.D., William R. Doucette, Ph.D., R.Ph., Julie M. Urmie, Ph.D., Yang Xie, Ph.D., John M. Brooks, Ph.D.
PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25
Richard R. Cline, Ph.D., Marcia M. Worley, Ph.D., Stephen W. Schondelmeyer, Pharm.D., Ph.D., Jon C. Schommer, Ph.D., Tom A. Larson, Pharm.D., Donald L. Uden, Pharm.D., Ronald S. Hadsall, Ph.D.
Patient satisfaction with a pharmacist-provided telephone medication therapy management program
Leticia R. Moczygemba, Pharm.D., Ph.D., Jamie C. Barner, Ph.D., Carolyn M. Brown, Ph.D., Kenneth A. Lawson, Ph.D., Evelyn R. Gabrillo, Pharm.D., Paul Godley, Pharm.D., Michael Johnsrud, Ph.D.
Development of a scale to measure pharmacists’ self-efficacy in performing medication therapy management services
Beth A. Martin, R.Ph., Ph.D., Michelle A. Chui, Pharm.D., Ph.D., Joshua M. Thorpe, M.P.H., Ph.D., David A. Mott, R.Ph., Ph.D., David H. Kreling, Ph.D.
About Research in Social & Administrative Pharmacy
Research in Social and Administrative Pharmacy (RSAP) is a quarterly publication featuring original scientific reports and comprehensive review articles in the social and administrative pharmaceutical sciences. Topics of interest include outcomes evaluation of products, programs, or services; pharmacoepidemiology; medication adherence; direct-to-consumer advertising of prescription medications; disease state management; health systems reform; drug marketing; medication distribution systems such as e-prescribing; web-based pharmaceutical/medical services; drug commerce and re-importation; and health professions workforce issues.
Guided by Editor-in-Chief Shane P. Desselle, R.Ph., Ph.D., FAPhA, and an eminent international editorial board, RSAP has become a widely recognized venue for publishing articles that proffer new models to guide existing research, make methodological arguments, or otherwise describe the results of rigorous theory-building research. Papers that translate the results of such research into information useful for practitioners are also welcome. RSAP encourages submission of manuscripts from multi-disciplinary collaborators on projects whose goal is to address medication use policy. RSAP also publishes special thematic issues that will be of interest and benefit to its readers and to the community at large.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries. www.elsevier.com